VIDEO: Treatment approaches in FLT3-mutated acute myeloid leukemia
Click Here to Manage Email Alerts
Naval Daver, MD, spoke with Healio about updates in FLT3-mutated acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.
Daver said that during a presentation, Mark J. Levis, MD, PhD, professor of oncology, medicine and pharmacology in the division of hematologic malignancies at Johns Hopkins University School of Medicine, discussed new data on FLT3 inhibitors, including how to utilize them in the front-line setting.
Daver, professor and director of the Leukemia Research Alliance Program in the department of leukemia at The University of Texas MD Anderson Cancer Center, explained that Levis presented data from his clinic on “molecular [minimal residual disease (MRD)]-based data to incorporate targeted therapies after azacitidine/venetoclax [(Venclexta; Genentech, AbbVie)].
“Another approach that we at MD Anderson have been taking is to combine the drugs up front as a triple combination — azacitidine/venetoclax with gilteritinib [(Xospata, Astellas Pharma)] — which of course has the pros of adding much deeper responses early on, but one has to then be aware and manage the myelosuppression,” Daver added. “However, we do think that in the future, the approach of combining these agents may lead to better outcomes for a large proportion of patients.”
Reference:
- Levis MJ. FLT3 mutated AML unanswered questions. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 4-7, 2024; Houston.
Collapse
Healio Interviews
Click Here to Manage Email Alerts